Basic Info
  • Grade: pharmaceutical grade

    Factory Location: china

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Packaging Information: 1kg/bag

  • Sample Provided: no

    Payment Terms: Bank transfer

    2,4,5-Trifluorobenzyl bromide is an important intermediate in the synthesis of sitagliptin. Sitagliptin is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor developed by Merck and approved by the US FDA in October 2006 for the treatment of non-insulin-dependent (type II) diabetes. 2,4,5-trifluorobenzyl bromide is prepared by bromomethylation of 1,2,4-trifluorobenzene as raw material, which has more waste and needs to use highly toxic cyanide, and the process has certain safety risks.
Send your message to this supplier
  • From:
  • To:
    Chongqing Xingcan Pharmaceutical Technology Co., Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service